Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of kinesin-like 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding kinesin-like 1. Methods of using these compounds for modulation of kinesin-like 1 expression and for treatment of diseases associated with expression of kinesin-like 1 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of SLC26A2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SLC26A2. Methods of using these compounds for modulation of SLC26A2 expression and for diagnosis and treatment of disease associated with expression of SLC26A2 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of p70 S6 kinase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding p70 S6 kinase. Methods of using these compounds for modulation of p70 S6 kinase expression and for treatment of diseases associated with expression of p70 S6 kinase are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of Aurora B. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Aurora B. Methods of using these compounds for modulation of Aurora B expression and for diagnosis and treatment of diseases and conditions associated with expression of Aurora B are provided. Also provided are methods of using these compounds to modulate the growth of cancer cells, including p53-deficient cancer cells.

Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of TFAP2C. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TFAP2C. Methods of using these compounds for modulation of TFAP2C expression and for treatment of diseases associated with expression of TFAP2C are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of sterol regulatory element-binding protein-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding sterol regulatory element-binding protein-1. Methods of using these compounds for modulation of sterol regulatory element-binding protein-1 expression and for treatment of diseases associated with expression of sterol regulatory element-binding protein-1 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of Notch1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Notch1. Methods of using these compounds for modulation of Notch1 expression and for diagnosis and treatment of disease associated with expression Notch1 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of kinesin-like 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding kinesin-like 1. Methods of using these compounds for modulation of kinesin-like 1 expression and for treatment of diseases associated with expression of kinesin-like 1 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of Ephrin-B2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Ephrin-B2. Methods of using these compounds for modulation of Ephrin-B2 expression and for diagnosis and treatment of disease associated with expression of Ephrin-B2 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of Notch1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Notch1. Methods of using these compounds for modulation of Notch1 expression and for diagnosis and treatment of disease associated with expression Notch1 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Notch1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Notch1. Methods of using these compounds for modulation of Notch1 expression and for treatment of diseases associated with expression of Notch1 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of kinesin-like 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding kinesin-like 1. Methods of using these compounds for modulation of kinesin-like 1 expression and for treatment of diseases associated with expression of kinesin-like 1 are provided.

Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human mdm2. The compositions include antisense compounds targeted to nucleic acids encoding mdm2. Methods of using these oligonucleotides for inhibition of mdm2 expression and for treatment of diseases such as cancers associated with overexpression of mdm2 are provided.

Abstract: The present invention provides methods for inducing apoptosis and for treating conditions associated with insufficient apoptosis. These methods are based on the novel observation that inhibition of Jagged 2 induces apoptosis and causes cell death. Thus methods of use for Jagged 2 inhibitors are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of estrogen receptor beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding estrogen receptor beta. Methods of using these compounds for modulation of estrogen receptor beta expression and for treatment of diseases associated with expression of estrogen receptor beta are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Toll-like receptor 4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Toll-like receptor 4. Methods of using these compounds for modulation of Toll-like receptor 4 expression and for treatment of diseases associated with expression of Toll-like receptor 4 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Inhibitor-kappa B Kinase-beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Inhibitor-kappa B Kinase-beta. Methods of using these compounds for modulation of Inhibitor-kappa B Kinase-beta expression and for treatment of diseases associated with expression of Inhibitor-kappa B Kinase-beta are provided.

Abstract: The base plate module of an electromagnetic switching device, specifically a contactor, is mounted on a base plate (1). The base plate module contains the core (2) of the electromagnet, a magnet coil (5), a printed circuit board (10) with its connected ancillary devices, as well as the contact plugs (16, 17) and terminals (24, 25), both of which are accessible from the outside. Printed circuit board (10) is mounted on base plate (1) and is located between base plate (1) and core (2), which is mounted on the base plate. Strip conductors (12, 13, 14), on the side facing core (2), feature several spring-loaded stub contacts (19, 20) and/or contact plugs (21, 22), all of which are vertically mounted on circuit board (10). Flange (7) of coil module (6), which is oriented toward base plate (1), provided with terminals (23) of magnet coil (5). With magnet coil (5) in the mounted position, terminals (23) of magnet coil (5) are in contact with the spring-loaded stub contacts (19) of strip conductors (13).